ImmunityBio (IBRX) Accumulated Expenses (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Accumulated Expenses data on file, last reported at $48.2 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 72.84% year-over-year to $48.2 million in Q1 2026; TTM through Mar 2026 was $48.2 million, a 72.84% increase from a year earlier, with the FY2025 full-year figure at $46.8 million, up 15.42% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $48.2 million, up from $46.8 million in the prior quarter.
• Over the last five years, Accumulated Expenses for IBRX reached as high as $64.9 million in Q3 2023 and fell as low as $44000.0 in Q2 2024.
• Historically, Accumulated Expenses has averaged $41.4 million across 5 years, with a median of $43.6 million in 2025.
• Across the five-year window, Accumulated Expenses tumbled 99.93% in 2024 and surged 81047.73% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $41.8 million in 2022, then advanced by 2.11% to $42.7 million in 2023, then dropped by 4.98% to $40.6 million in 2024, then gained by 15.42% to $46.8 million in 2025, then rose by 2.92% to $48.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $48.2 million in Q1 2026, $46.8 million in Q4 2025, and $43.6 million in Q3 2025.